Claims
- 1. A method of reversing a clinical episode of a disease which is generally considered incurable in a subject, the method comprising:
(a) providing an immune-globulin preparation containing a detectable titre of antibodies to the disease which is generally considered incurable, (b) administering said immune-globulin preparation to the subject.
- 2. The method of claim 1, wherein said immune globulin preparation is selected from the group consisting of a pool of immunoglobulins from a plurality of donors, a monoclonal antibody preparation and immuno-globulins derived from a single donor.
- 3. The method of claim 1, wherein said immune-globulin preparation includes at least one immuno-globulin selected from the group consisting of IgG, IgM, IgA, and IgY.
- 4. The method of claim 2, further comprising recruiting said plurality of donors from a geographic area in which the disease which is generally considered incurable is endemic.
- 5. The method of claim 4, wherein said geographic area includes at least a portion of an area selected from the group consisting of the state of Israel and territories administered thereby.
- 6. The method of claim 1, wherein said disease which is generally considered incurable is a viral disease selected from the group consisting of West Nile Virus, Hepatitis A, Hepatitis B, Hepatitis C, HIV, RSV, CMV, HSV, ESV, VSV, Ebola and tick borne encephalitis.
- 7. The method of claim 1, wherein said administering is performed via a route of administration selected from the group consisting of intravenously, intraperitoneally, subcutaneously, intramuscularly, orally, intraocularly, intranasally, vaginally and rectally.
- 8. A pharmaceutical composition for reversing a clinical episode of a disease which is generally considered incurable in a subject, the composition comprising, as an active ingredient, a therapeutically effective amount of an immune-globulin preparation containing a detectable titre of antibodies to the disease which is generally considered incurable and a physiologically acceptable carrier and/or excipient.
- 9. The pharmaceutical composition of claim 8, wherein said immune globulin preparation is selected from the group consisting of a pool of immuno-globulins from a plurality of donors, a monoclonal antibody preparation and immuno-globulins derived from a single donor.
- 10. The pharmaceutical composition of claim 8, wherein said immune-globulin preparation includes at least one immuno-globulin selected from the group consisting of IgG, TgM, IgA, and IgY.
- 11. The pharmaceutical composition of claim 9, wherein said plurality of donors are recruited from a geographic area in which the disease which is generally considered incurable is endemic.
- 12. The pharmaceutical composition of claim 11, wherein said geographic area includes at least a portion of an area selected from the group consisting of the state of Israel and territories administered thereby.
- 13. The pharmaceutical composition of claim 8, wherein said disease which is generally considered incurable is a viral disease selected from the group consisting of West Nile Virus, Hepatitis A, Hepatitis B, Hepatitis C, HIV, RSV, CMV, HSV, ESV, VSV, Ebola and tick borne encephalitis.
- 14. The pharmaceutical composition of claim 8, wherein said administering is performed via a route of administration selected from the group consisting of intravenously, intraperitoneally, subcutaneously, intramuscularly, orally, intraocularly, intranasally, vaginally and rectally.
- 15. An article of manufacture comprising packaging material and a pharmaceutical composition identified for reversing a clinical episode of a disease which is generally considered incurable in a subject being contained within said packaging material, said pharmaceutical composition including, as an active ingredient, a therapeutically effective amount of an immune-globulin preparation containing a detectable titre of antibodies to the disease which is generally considered incurable and a pharmaceutically acceptable carrier.
- 16. The article of manufacture of claim 15, wherein said immune globulin preparation is selected from the group consisting of a pool of immuno-globulins from a plurality of donors, a monoclonal antibody preparation and immuno-globulins derived from a single donor.
- 17. The article of manufacture of claim 15, wherein said immune-globulin preparation includes at least one immuno-globulin selected from the group consisting of IgG, IgM, IgA, and IgY.
- 18. The article of manufacture of claim 9, further comprising recruiting said plurality of donors from a geographic area in which the disease which is generally considered incurable is endemic.
- 19. The article of manufacture of claim 15, wherein said disease which is generally considered incurable is a viral disease selected from the group consisting of West Nile Virus, Hepatitis A, Hepatitis B, Hepatitis C, HIV, RSV, CMV, HSV, ESV, VSV, Ebola and tick borne encephalitis.
- 20. The article of manufacture of claim 15, wherein said administering is performed via a route of administration selected from the group consisting of intravenously, intraperitoneally, subcutaneously, intramuscularly, orally, intranasally, intraocularly, vaginally and rectally.
Parent Case Info
[0001] This application claims priority from U.S. Patent Application No. 60/377,953 filed on May 7, 2002 and currently pending.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60377953 |
May 2002 |
US |